12:00 AM
 | 
Jun 19, 2000
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Isis preclinical data

ISIP's GeneTrove target validation division said that in diabetic mice, the company's anti-PTEN antisense molecule gave a significant reduction...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >